Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Piper Sandler Downgrades NGM Biopharmaceuticals to Neutral

Piper Sandler analyst Swapnil Malekar downgrades NGM Biopharmaceuticals (NASDAQ:NGM) from Overweight to Neutral.
byBenzinga Newsdesk
October 17, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Piper Sandler analyst Swapnil Malekar downgrades NGM Biopharmaceuticals (NASDAQ:NGM) from Overweight to Neutral.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0